Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 98 entries
Sorted by: Best Match Show Resources per page
Microbiologically documented infections following peripheral blood stem cell transplantation: single center experience.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Altuntaş F, Yıldız O, Eser B, Alp E, Sarı İ, Çetin M, Sümerkan B, Ünal A.
PMID: 27264835
Turk J Haematol. 2005 Sep 05;22(3):133-45.

This study was performed to assess the incidence of infectious complications in patients undergoing autologous and allogeneic hematopoietic stem cell transplantation (HSCT). The characteristics of microbiologically documented infections in 114 consecutive patients undergoing HSCT (84 autologous, 30 allogeneic) were...

Cite
Altuntaş F, Yıldız O, Eser B, et al. Periferik kök hücre naklinde mikrobiyolojik kanıtlanmış infeksiyonlar: Tek merkez deneyimi. Microbiologically documented infections following peripheral blood stem cell transplantation: single center experience. Turk J Haematol. 2005;22(3):133-45
Altuntaş, F., Yıldız, O., Eser, B., Alp, E., Sarı, �. �., Çetin, M., Sümerkan, B., & Ünal, A. (2005). Periferik kök hücre naklinde mikrobiyolojik kanıtlanmış infeksiyonlar: Tek merkez deneyimi. Microbiologically documented infections following peripheral blood stem cell transplantation: single center experience. Turkish journal of haematology : official journal of Turkish Society of Haematology, 22(3), 133-45.
Altuntaş, Fevzi, et al. "Periferik kök hücre naklinde mikrobiyolojik kanıtlanmış infeksiyonlar: Tek merkez deneyimi." Microbiologically documented infections following peripheral blood stem cell transplantation: single center experience. Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 22,3 (2005): 133-45.
Altuntaş F, Yıldız O, Eser B, Alp E, Sarı İ, Çetin M, Sümerkan B, Ünal A. Periferik kök hücre naklinde mikrobiyolojik kanıtlanmış infeksiyonlar: Tek merkez deneyimi. Microbiologically documented infections following peripheral blood stem cell transplantation: single center experience. Turk J Haematol. 2005 Sep 05;22(3):133-45. PMID: 27264835.
Copy Download .nbib Format: NLM
Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Joosub I, Gray A, Crisostomo A, Salam A.
PMID: 26702257
Saudi Pharm J. 2015 Nov;23(6):626-34. doi: 10.1016/j.jsps.2015.02.016. Epub 2015 Feb 28.

AIM: The aim of this study was to compare the costs of management of moderate to severe infections in patients treated with imipenem/cilastatin (IC) and meropenem (MEM). Pharmacoeconomic studies in Saudi Arabia are scarce. The current hospital formulary contains...

Cite
Joosub I, Gray A, Crisostomo A, et al. Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia. Saudi Pharm J. 2015;23(6):626-34doi: 10.1016/j.jsps.2015.02.016.
Joosub, I., Gray, A., Crisostomo, A., & Salam, A. (2015). Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 23(6), 626-34. https://doi.org/10.1016/j.jsps.2015.02.016
Joosub, Imraan, et al. "Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 23,6 (2015): 626-34. doi: https://doi.org/10.1016/j.jsps.2015.02.016
Joosub I, Gray A, Crisostomo A, Salam A. Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia. Saudi Pharm J. 2015 Nov;23(6):626-34. doi: 10.1016/j.jsps.2015.02.016. Epub 2015 Feb 28. PMID: 26702257; PMCID: PMC4669425.
Copy Download .nbib Format: NLM
Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital.

Annals of clinical microbiology and antimicrobials

Gonlugur U, Bakici MZ, Ozdemir L, Akkurt I, Icagasioglu S, Gultekin F.
PMID: 12665428
Ann Clin Microbiol Antimicrob. 2003 Mar 07;2:5. doi: 10.1186/1476-0711-2-5.

BACKGROUND: Lower respiratory tract infections due to Pseudomonas aeruginosa have a high mortality rate. Antibacterial activity of various antibiotics against P. aeruginosa isolated from each hospital depends on the variety or amount of antibiotics used in each hospital.METHOD: A...

Cite
Gonlugur U, Bakici MZ, Ozdemir L, et al. Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital. Ann Clin Microbiol Antimicrob. 2003;2:5doi: 10.1186/1476-0711-2-5.
Gonlugur, U., Bakici, M. Z., Ozdemir, L., Akkurt, I., Icagasioglu, S., & Gultekin, F. (2003). Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital. Annals of clinical microbiology and antimicrobials, 25. https://doi.org/10.1186/1476-0711-2-5
Gonlugur, Ugur, et al. "Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital." Annals of clinical microbiology and antimicrobials vol. 2 (2003): 5. doi: https://doi.org/10.1186/1476-0711-2-5
Gonlugur U, Bakici MZ, Ozdemir L, Akkurt I, Icagasioglu S, Gultekin F. Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital. Ann Clin Microbiol Antimicrob. 2003 Mar 07;2:5. doi: 10.1186/1476-0711-2-5. PMID: 12665428; PMCID: PMC152644.
Copy Download .nbib Format: NLM
[Clinical Characteristics of Extended-spectrum beta-lactamase Producing Shigella sonnei Infection Outbreaked in Chungju Area.].

The Korean journal of laboratory medicine

Hong SJ, Lee CH, Wang JH, Song W, Jung SH.
PMID: 18156720
Korean J Lab Med. 2006 Jun;26(3):168-73. doi: 10.3343/kjlm.2006.26.3.168.

BACKGROUND: An outbreak of extended-spectrum beta-lactamase (ESBL)-producing Shigella sonnei enteritis, especially in pediatric populations, was unprecedented not only in Korea, but also throughout the world in the past. This study was intended to devise a management guideline for shigellosis...

Cite
Hong SJ, Lee CH, Wang JH, et al. [Clinical Characteristics of Extended-spectrum beta-lactamase Producing Shigella sonnei Infection Outbreaked in Chungju Area.]. Korean J Lab Med. 2006;26(3):168-73doi: 10.3343/kjlm.2006.26.3.168.
Hong, S. J., Lee, C. H., Wang, J. H., Song, W., & Jung, S. H. (2006). [Clinical Characteristics of Extended-spectrum beta-lactamase Producing Shigella sonnei Infection Outbreaked in Chungju Area.]. The Korean journal of laboratory medicine, 26(3), 168-73. https://doi.org/10.3343/kjlm.2006.26.3.168
Hong, Seong Jin, et al. "[Clinical Characteristics of Extended-spectrum beta-lactamase Producing Shigella sonnei Infection Outbreaked in Chungju Area.]." The Korean journal of laboratory medicine vol. 26,3 (2006): 168-73. doi: https://doi.org/10.3343/kjlm.2006.26.3.168
Hong SJ, Lee CH, Wang JH, Song W, Jung SH. [Clinical Characteristics of Extended-spectrum beta-lactamase Producing Shigella sonnei Infection Outbreaked in Chungju Area.]. Korean J Lab Med. 2006 Jun;26(3):168-73. doi: 10.3343/kjlm.2006.26.3.168. Korean. PMID: 18156720.
Copy Download .nbib Format: NLM
Association between ward-specific antimicrobial use density and methicillin-resistant Staphylococcu aureus surveillance: a 60-month study.

Infection and drug resistance

Yoshida J, Kikuchi T, Matsubara N, Asano I, Ogami N.
PMID: 23901286
Infect Drug Resist. 2013 Jul 23;6:59-66. doi: 10.2147/IDR.S45843. Print 2013.

It is not known whether or not ward-specific antimicrobial use density (AUD) affects the ratio of methicillin-resistant Staphylococcus aureus (MRSA) in culture-positive S. aureus. A 60-month study was attempted to ascertain the association between inpatient MRSA ratio and ward-specific...

Cite
Yoshida J, Kikuchi T, Matsubara N, et al. Association between ward-specific antimicrobial use density and methicillin-resistant Staphylococcu aureus surveillance: a 60-month study. Infect Drug Resist. 2013;6:59-66doi: 10.2147/IDR.S45843.
Yoshida, J., Kikuchi, T., Matsubara, N., Asano, I., & Ogami, N. (2013). Association between ward-specific antimicrobial use density and methicillin-resistant Staphylococcu aureus surveillance: a 60-month study. Infection and drug resistance, 659-66. https://doi.org/10.2147/IDR.S45843
Yoshida, Junichi, et al. "Association between ward-specific antimicrobial use density and methicillin-resistant Staphylococcu aureus surveillance: a 60-month study." Infection and drug resistance vol. 6 (2013): 59-66. doi: https://doi.org/10.2147/IDR.S45843
Yoshida J, Kikuchi T, Matsubara N, Asano I, Ogami N. Association between ward-specific antimicrobial use density and methicillin-resistant Staphylococcu aureus surveillance: a 60-month study. Infect Drug Resist. 2013 Jul 23;6:59-66. doi: 10.2147/IDR.S45843. Print 2013. PMID: 23901286; PMCID: PMC3726436.
Copy Download .nbib Format: NLM
Patterns of antibiotic use and administration in hospitalized patients in Jordan.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Jarab AS, Mukattash TL, Nusairat B, Shawaqfeh M, Farha RA.
PMID: 30202214
Saudi Pharm J. 2018 Sep;26(6):764-770. doi: 10.1016/j.jsps.2018.04.009. Epub 2018 Apr 18.

BACKGROUND: Inappropriate use of antibiotics is the leading cause of emergence of resistance. It has been estimated that two million people in the United States had infection with resistant bacteria, resulting in 23,000 deaths annually. In Jordan, more than...

Cite
Jarab AS, Mukattash TL, Nusairat B, et al. Patterns of antibiotic use and administration in hospitalized patients in Jordan. Saudi Pharm J. 2018;26(6):764-770doi: 10.1016/j.jsps.2018.04.009.
Jarab, A. S., Mukattash, T. L., Nusairat, B., Shawaqfeh, M., & Farha, R. A. (2018). Patterns of antibiotic use and administration in hospitalized patients in Jordan. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 26(6), 764-770. https://doi.org/10.1016/j.jsps.2018.04.009
Jarab, Anan S, et al. "Patterns of antibiotic use and administration in hospitalized patients in Jordan." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 26,6 (2018): 764-770. doi: https://doi.org/10.1016/j.jsps.2018.04.009
Jarab AS, Mukattash TL, Nusairat B, Shawaqfeh M, Farha RA. Patterns of antibiotic use and administration in hospitalized patients in Jordan. Saudi Pharm J. 2018 Sep;26(6):764-770. doi: 10.1016/j.jsps.2018.04.009. Epub 2018 Apr 18. PMID: 30202214; PMCID: PMC6128802.
Copy Download .nbib Format: NLM
Pathogen characteristics and its sensitivity against antimicrobial agents in fatal bacterial granuloma after eyelid trauma in vitro.

International journal of ophthalmology

Xu XL, Liu JY, Gao TW, Zhang PL, Qi XL, Cheng XD, Hao XK.
PMID: 22553692
Int J Ophthalmol. 2011;4(4):410-2. doi: 10.3980/j.issn.2222-3959.2011.04.18. Epub 2011 Aug 18.

AIM: To understand the pathogen characteristics and its sensitivity against antimicrobial agents in fatal bacterial granuloma after eyelid trauma (FBGT) in vitro, and to provide laboratory evidence for diagnosis.METHODS: The FBGT pathogens were isolaated and cultured with reformed rabbit-brain...

Cite
Xu XL, Liu JY, Gao TW, et al. Pathogen characteristics and its sensitivity against antimicrobial agents in fatal bacterial granuloma after eyelid trauma in vitro. Int J Ophthalmol. 2011;4(4):410-2doi: 10.3980/j.issn.2222-3959.2011.04.18.
Xu, X. L., Liu, J. Y., Gao, T. W., Zhang, P. L., Qi, X. L., Cheng, X. D., & Hao, X. K. (2011). Pathogen characteristics and its sensitivity against antimicrobial agents in fatal bacterial granuloma after eyelid trauma in vitro. International journal of ophthalmology, 4(4), 410-2. https://doi.org/10.3980/j.issn.2222-3959.2011.04.18
Xu, Xiu-Li, et al. "Pathogen characteristics and its sensitivity against antimicrobial agents in fatal bacterial granuloma after eyelid trauma in vitro." International journal of ophthalmology vol. 4,4 (2011): 410-2. doi: https://doi.org/10.3980/j.issn.2222-3959.2011.04.18
Xu XL, Liu JY, Gao TW, Zhang PL, Qi XL, Cheng XD, Hao XK. Pathogen characteristics and its sensitivity against antimicrobial agents in fatal bacterial granuloma after eyelid trauma in vitro. Int J Ophthalmol. 2011;4(4):410-2. doi: 10.3980/j.issn.2222-3959.2011.04.18. Epub 2011 Aug 18. PMID: 22553692; PMCID: PMC3340880.
Copy Download .nbib Format: NLM
A Comparative Study on Antibiotic Resistance of Klebsiella Strains from Surgical and Intensive Care Wards.

Current health sciences journal

Cristea OM, Zlatian OM, Dinescu SN, Bălăşoiu AT, Avramescu C, Bălăşoiu M, Niculescu M, Calina D.
PMID: 30568829
Curr Health Sci J. 2016 Apr-Jun;42(2):169-179. doi: 10.12865/CHSJ.42.02.09. Epub 2016 Jun 28.

INTRODUCTION: Klebsiella infections are common in Intensive Care Unit (ICU) and surgical wards. In order to establish the prophylaxis protocols, we must know the prevalence of infections and the antibiotic resistance profiles.MATERIAL AND METHODS: This cross-sectional study included isolates...

Cite
Cristea OM, Zlatian OM, Dinescu SN, et al. A Comparative Study on Antibiotic Resistance of Klebsiella Strains from Surgical and Intensive Care Wards. Curr Health Sci J. 2016;42(2):169-179doi: 10.12865/CHSJ.42.02.09.
Cristea, O. M., Zlatian, O. M., Dinescu, S. N., Bălăşoiu, A. T., Avramescu, C., Bălăşoiu, M., Niculescu, M., & Calina, D. (2016). A Comparative Study on Antibiotic Resistance of Klebsiella Strains from Surgical and Intensive Care Wards. Current health sciences journal, 42(2), 169-179. https://doi.org/10.12865/CHSJ.42.02.09
Cristea, O M, et al. "A Comparative Study on Antibiotic Resistance of Klebsiella Strains from Surgical and Intensive Care Wards." Current health sciences journal vol. 42,2 (2016): 169-179. doi: https://doi.org/10.12865/CHSJ.42.02.09
Cristea OM, Zlatian OM, Dinescu SN, Bălăşoiu AT, Avramescu C, Bălăşoiu M, Niculescu M, Calina D. A Comparative Study on Antibiotic Resistance of Klebsiella Strains from Surgical and Intensive Care Wards. Curr Health Sci J. 2016 Apr-Jun;42(2):169-179. doi: 10.12865/CHSJ.42.02.09. Epub 2016 Jun 28. PMID: 30568829; PMCID: PMC6256155.
Copy Download .nbib Format: NLM
The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms.

Current infectious disease reports

Noval M, Banoub M, Claeys KC, Heil E.
PMID: 31933158
Curr Infect Dis Rep. 2020 Jan 13;22(1):1. doi: 10.1007/s11908-020-0710-9.

PURPOSE OF REVIEW: Resistant gram-negative infections are becoming increasingly difficult to treat, prompting increased focus on drug development. This review will focus primarily on the new beta-lactam agents developed in the past 5 years that target multidrug-resistant (MDR) gram-negative...

Cite
Noval M, Banoub M, Claeys KC, et al. The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms. Curr Infect Dis Rep. 2020;22(1):1doi: 10.1007/s11908-020-0710-9.
Noval, M., Banoub, M., Claeys, K. C., & Heil, E. (2020). The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms. Current infectious disease reports, 22(1), 1. https://doi.org/10.1007/s11908-020-0710-9
Noval, Mandee, et al. "The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms." Current infectious disease reports vol. 22,1 (2020): 1. doi: https://doi.org/10.1007/s11908-020-0710-9
Noval M, Banoub M, Claeys KC, Heil E. The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms. Curr Infect Dis Rep. 2020 Jan 13;22(1):1. doi: 10.1007/s11908-020-0710-9. PMID: 31933158.
Copy Download .nbib Format: NLM
Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target .

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Hayden DA, White BP, Bennett KK.
PMID: 34752560
J Pharm Technol. 2020 Oct;36(5):202-210. doi: 10.1177/8755122520934726. Epub 2020 Jun 17.

No abstract available.

Cite
Hayden DA, White BP, Bennett KK. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target . J Pharm Technol. 2020;36(5):202-210doi: 10.1177/8755122520934726.
Hayden, D. A., White, B. P., & Bennett, K. K. (2020). Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target . The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 36(5), 202-210. https://doi.org/10.1177/8755122520934726
Hayden, Dillon A, et al. "Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target ." The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians vol. 36,5 (2020): 202-210. doi: https://doi.org/10.1177/8755122520934726
Hayden DA, White BP, Bennett KK. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target . J Pharm Technol. 2020 Oct;36(5):202-210. doi: 10.1177/8755122520934726. Epub 2020 Jun 17. PMID: 34752560; PMCID: PMC7453473.
Copy Download .nbib Format: NLM
The therapeutic effect of Cilastatin on drug-induced nephrotoxicity: a new perspective.

European review for medical and pharmacological sciences

Becerir T, Tokgün O, Yuksel S.
PMID: 34533819
Eur Rev Med Pharmacol Sci. 2021 Sep;25(17):5436-5447. doi: 10.26355/eurrev_202109_26651.

OBJECTIVE: By creating nephrotoxicity models with cisplatin, vancomycin, and gentamicin in HK-2 (human renal proximal tubule cell) and HEK293T (human embryonic kidney epithelial cells) cell lines, we aimed to evaluate the effect of cilastatin on recovery of cell damage...

Cite
Becerir T, Tokgün O, Yuksel S. The therapeutic effect of Cilastatin on drug-induced nephrotoxicity: a new perspective. Eur Rev Med Pharmacol Sci. 2021;25(17):5436-5447doi: 10.26355/eurrev_202109_26651.
Becerir, T., Tokgün, O., & Yuksel, S. (2021). The therapeutic effect of Cilastatin on drug-induced nephrotoxicity: a new perspective. European review for medical and pharmacological sciences, 25(17), 5436-5447. https://doi.org/10.26355/eurrev_202109_26651
Becerir, T, et al. "The therapeutic effect of Cilastatin on drug-induced nephrotoxicity: a new perspective." European review for medical and pharmacological sciences vol. 25,17 (2021): 5436-5447. doi: https://doi.org/10.26355/eurrev_202109_26651
Becerir T, Tokgün O, Yuksel S. The therapeutic effect of Cilastatin on drug-induced nephrotoxicity: a new perspective. Eur Rev Med Pharmacol Sci. 2021 Sep;25(17):5436-5447. doi: 10.26355/eurrev_202109_26651. PMID: 34533819.
Copy Download .nbib Format: NLM
Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol.

Clinical pharmacokinetics

Bilal M, El Tabei L, Büsker S, Krauss C, Fuhr U, Taubert M.
PMID: 34420182
Clin Pharmacokinet. 2021 Dec;60(12):1495-1508. doi: 10.1007/s40262-021-01063-5. Epub 2021 Aug 22.

Cefiderocol is a new broad-spectrum cephalosporin antibiotic with promising activity against various Gram-negative bacteria including carbapenem-resistant strains. A chlorocatechol group in the C-3 side chain provides cefiderocol with a siderophore activity, improving its stability against β-lactamases and facilitating the...

Cite
Bilal M, El Tabei L, Büsker S, et al. Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. Clin Pharmacokinet. 2021;60(12):1495-1508doi: 10.1007/s40262-021-01063-5.
Bilal, M., El Tabei, L., Büsker, S., Krauss, C., Fuhr, U., & Taubert, M. (2021). Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. Clinical pharmacokinetics, 60(12), 1495-1508. https://doi.org/10.1007/s40262-021-01063-5
Bilal, Muhammad, et al. "Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol." Clinical pharmacokinetics vol. 60,12 (2021): 1495-1508. doi: https://doi.org/10.1007/s40262-021-01063-5
Bilal M, El Tabei L, Büsker S, Krauss C, Fuhr U, Taubert M. Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. Clin Pharmacokinet. 2021 Dec;60(12):1495-1508. doi: 10.1007/s40262-021-01063-5. Epub 2021 Aug 22. PMID: 34420182; PMCID: PMC8613110.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 98 entries